509
Participants
Start Date
January 12, 2006
Primary Completion Date
November 16, 2020
Study Completion Date
November 16, 2020
Infliximab
Initiation of infliximab in any dose and frequency of administration. Could be discontinued for safety reasons and replaced by etanercept.
Sulfasalazine + Hydroxychloroquine
Initiation of sulfasalazine and hydroxychloroquine not more than 180 days apart, in any dose and frequency of administration. Any one of the two drugs could be discontinued. while continuing the other, or both could be replaced by cyclosporine, for safety reasons.
Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Unit, Stockholm
Harvard Medical School (HMS and HSDM)
OTHER
Karolinska Institutet
OTHER